{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:02:12Z","timestamp":1790276532773,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"French Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Antihypertensive therapy (AHT) is usually lifelong. The feasibility of discontinuing AHT in selected individuals is insufficiently studied. The aims are to assess the feasibility of discontinuing AHT in patients on monotherapy or low-dose dual therapy, and identify factors associated with maintaining normotension without treatment for one year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This prospective, multicentre, non-randomized, open-label study assessed stopping AHT in individuals without self-reported cardiovascular risk factors (other than hypertension) or target organ damage, on monotherapy or low-dose dual AHT. The primary endpoint was maintaining normotension (&amp;lt;135\/85\u2005mmHg) for one year (with measurements at 1, 3, 6, 9, and 12 months) based on home blood pressure measurements (HBPM). Factors associated with success and failure of maintaining normotension were explored. Among 401 screened individuals, 218 (54.4%) were included after confirmation of controlled blood pressure (BP) by HBPM at baseline and their AHT was discontinued within 3 days. Two hundred three participants had available BP measurements throughout the follow-up and were analysed. Their mean age was 58.2 (\u00b110.1) years, and 47.3% were women. Of these 203, 73 (36%) maintained BP &amp;lt; 135\/85\u2005mmHg for one year without AHT while 130 patients (64%) required resumption of their AHT during the follow-up. Baseline HBPM predicted BP values at one year, while office BP or white-coat hypertension did not. Patients with systolic HBPM &amp;lt; 120\u2005mmHg prior to AHT discontinuation had a 60% chance of maintaining normal BP, compared to 23% with systolic HBPM \u2265 120\u2005mmHg. One patient with systolic HBPM &amp;gt; 120\u2005mmHg at baseline experienced an ischaemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>About one-third of individuals on monotherapy or low-dose dual AHT who discontinued treatment maintained controlled BP after one year. Discontinuing AHT may be considered in selected individuals with HBPM below 120\u2005mmHg, provided close BP monitoring is performed, particularly within the first year of AHT withdrawal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>Clinicaltrial.gov registration number: NCT02268071.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf511","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:51:58Z","timestamp":1755777118000},"page":"1274-1286","source":"Crossref","is-referenced-by-count":1,"title":["Stopping antihypertensive Treatment amOng hypertensive patients in Primary care: the STOP-Trial"],"prefix":"10.1093","volume":"33","author":[{"given":"Jean-Marc","family":"Boivin","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigations Cliniques Plurith\u00e9matique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigations Cliniques Plurith\u00e9matique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]},{"name":"Department of Physiology and Cardiothoracic Surgery, Cardiovascular R&D Centre\u2014UnIC@RISE, Faculty of Medicine of the University of Porto , Porto ,","place":["Portugal"]},{"name":"Heart Failure Clinic, Internal Medicine Department, Unidade Local de Sa\u00fade de Gaia\/Espinho , Gaia ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilucy","family":"Lopez-Sublet","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Avicenne, Centre d'Excellence Europ\u00e9en en Hypertension Art\u00e9rielle, Service de M\u00e9decine Interne; INSERM UMR 942 MASCOT, Paris 13-Universit\u00e9 Paris Nord , Bobigny, France"},{"name":"FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Duarte","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigations Cliniques Plurith\u00e9matique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigations Cliniques Plurith\u00e9matique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-7932","authenticated-orcid":false,"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigations Cliniques Plurith\u00e9matique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]},{"name":"Medical Specialties and Nephrology Departments, Princess Grace Hospital , Monaco ,","place":["Monaco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-2057","authenticated-orcid":false,"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigations Cliniques Plurith\u00e9matique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"2026051513425274900_zwaf511-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","journal-title":"Lancet"},{"key":"2026051513425274900_zwaf511-B2","author":"World Health Organization"},{"key":"2026051513425274900_zwaf511-B3","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/HJH.0000000000002843","article-title":"2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement","volume":"39","author":"Stergiou","year":"2021","journal-title":"J Hypertens"},{"key":"2026051513425274900_zwaf511-B4","first-page":"e1","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"25","author":"McEvoy","year":"2024","journal-title":"G Ital Cardiol (Rome)"},{"key":"2026051513425274900_zwaf511-B5","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026051513425274900_zwaf511-B6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/CIRCRESAHA.118.313219","article-title":"Blood pressure measurement and treatment decisions","volume":"124","author":"Kario","year":"2019","journal-title":"Circ Res"},{"key":"2026051513425274900_zwaf511-B7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.amjmed.2023.09.015","article-title":"Controversies in hypertension V: resistant and refractory hypertension","volume":"137","author":"Filippone","year":"2024","journal-title":"Am J Med"},{"key":"2026051513425274900_zwaf511-B8","first-page":"130","article-title":"Epidemiology of hypertension in France: high prevalence and lack of public awareness","volume":"8","author":"Oli\u00e9","year":"2023","journal-title":"Bulletin Epid\u00e9miologique Hebdomadaire BEH"},{"key":"2026051513425274900_zwaf511-B9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1097\/HJH.0000000000002783","article-title":"Therapeutic inertia in the management of hypertension in primary care","volume":"39","author":"Ali","year":"2021","journal-title":"J Hypertens"},{"key":"2026051513425274900_zwaf511-B10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/HJH.0000000000002830","article-title":"Therapeutic inertia in hypertension management\u2014status quo in primary care","volume":"39","author":"Schlaich","year":"2021","journal-title":"J Hypertens"},{"key":"2026051513425274900_zwaf511-B11","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/jch.14699","article-title":"Uncontrolled blood pressure and therapeutic inertia in treated hypertensive patients: a retrospective cohort study using a UK general practice database","volume":"25","author":"Darricarrere","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026051513425274900_zwaf511-B12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00004872-198806000-00001","article-title":"The effect of withdrawing antihypertensive therapy: a review","volume":"6","author":"Fletcher","year":"1988","journal-title":"J Hypertens"},{"key":"2026051513425274900_zwaf511-B13","first-page":"977","article-title":"Stopping drug treatment of hypertension: experience in 18 British general practices","volume":"49","author":"Aylett","year":"1999","journal-title":"Br J Gen Pract"},{"key":"2026051513425274900_zwaf511-B14","first-page":"CD012572","article-title":"Withdrawal of antihypertensive drugs in older people","volume":"3","author":"Reeve","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026051513425274900_zwaf511-B15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/ageing\/afv199","article-title":"Effect of discontinuation of antihypertensive medication on orthostatic hypotension in older persons with mild cognitive impairment: the DANTE Study Leiden","volume":"45","author":"Moonen","year":"2016","journal-title":"Age Ageing"},{"key":"2026051513425274900_zwaf511-B16","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1001\/jamainternmed.2015.4103","article-title":"Effect of discontinuation of antihypertensive treatment in elderly people on cognitive functioning\u2014the DANTE Study Leiden: a randomized clinical trial","volume":"175","author":"Moonen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026051513425274900_zwaf511-B17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2015.7517","article-title":"Polypharmacy in the aging patient: management of hypertension in octogenarians","volume":"314","author":"Benetos","year":"2015","journal-title":"JAMA"},{"key":"2026051513425274900_zwaf511-B18","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.1991.03460120080040","article-title":"Antihypertensive therapy. To stop or not to stop?","volume":"265","author":"Schmieder","year":"1991","journal-title":"JAMA"},{"key":"2026051513425274900_zwaf511-B19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0895-7061(02)03143-6","article-title":"Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study (ANBP2)","volume":"16","author":"Nelson","year":"2003","journal-title":"Am J Hypertens"},{"key":"2026051513425274900_zwaf511-B20","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1097\/HJH.0000000000001405","article-title":"Withdrawal of antihypertensive medication: a systematic review","volume":"35","author":"van der Wardt","year":"2017","journal-title":"J Hypertens"},{"key":"2026051513425274900_zwaf511-B21","doi-asserted-by":"crossref","first-page":"107003","DOI":"10.1016\/j.phrs.2023.107003","article-title":"The 2023 European Society of Hypertension guidelines for high blood pressure\u2014what\u2019s new on diagnostic and therapeutic approaches","volume":"199","author":"Grassi","year":"2024","journal-title":"Pharmacol Res"},{"key":"2026051513425274900_zwaf511-B22","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","article-title":"Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study","volume":"388","author":"Vidal-Petiot","year":"2016","journal-title":"Lancet"},{"key":"2026051513425274900_zwaf511-B23","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1097\/HJH.0b013e32834b7efb","article-title":"Influence of the recommendations on the implementation of home blood pressure measurement by French general practitioners: a 2004\u20132009 longitudinal survey","volume":"29","author":"Boivin","year":"2011","journal-title":"J Hypertens"},{"key":"2026051513425274900_zwaf511-B24","doi-asserted-by":"crossref","first-page":"e0220460","DOI":"10.1371\/journal.pone.0220460","article-title":"Implementation of home blood pressure monitoring among French GPs: a long and winding road","volume":"14","author":"Dugelay","year":"2019","journal-title":"PLoS One"},{"key":"2026051513425274900_zwaf511-B25","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s41440-023-01259-1","article-title":"Current realities of home blood pressure monitoring from physicians\u2019 perspectives: results from Asia HBPM survey 2020","volume":"46","author":"Wang","year":"2023","journal-title":"Hypertens Res"},{"key":"2026051513425274900_zwaf511-B26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11906-019-0916-0","article-title":"Implementing home blood pressure monitoring into clinical practice","volume":"21","author":"Liyanage-Don","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"2026051513425274900_zwaf511-B27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3122\/jabfm.2022.02.210318","article-title":"Blood pressure checks for diagnosing hypertension: health professionals\u2019 knowledge, beliefs, and practices","volume":"35","author":"Green","year":"2022","journal-title":"J Am Board Fam Med"},{"key":"2026051513425274900_zwaf511-B28","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1038\/s41598-023-31861-9","article-title":"The long-term reproducibility of the white-coat effect on blood pressure as a continuous variable from the Ohasama Study","volume":"13","author":"Satoh","year":"2023","journal-title":"Sci Rep"},{"key":"2026051513425274900_zwaf511-B29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4070\/kcj.2016.46.3.365","article-title":"Higher blood pressure variability in white coat hypertension; from the Korean ambulatory blood pressure monitoring registry","volume":"46","author":"Kang","year":"2016","journal-title":"Korean Circ J"},{"key":"2026051513425274900_zwaf511-B30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/M14-2803","article-title":"Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality: a cohort study","volume":"163","author":"Muntner","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026051513425274900_zwaf511-B31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)60308-X","article-title":"Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension","volume":"375","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"2026051513425274900_zwaf511-B32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/ajh\/hpx221","article-title":"Real world home blood pressure variability in over 56,000 individuals with nearly 17 million measurements","volume":"31","author":"Kim","year":"2018","journal-title":"Am J Hypertens"},{"key":"2026051513425274900_zwaf511-B33","first-page":"170","article-title":"L\u2019hypertension art\u00e9rielle en France: pr\u00e9valence, traitement et contr\u00f4le en 2015 et \u00e9volutions depuis 2006","volume":"10","author":"Perrine","year":"2018","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"2026051513425274900_zwaf511-B34","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa060838","article-title":"Feasibility of treating prehypertension with an angiotensin-receptor blocker","volume":"354","author":"Julius","year":"2006","journal-title":"N Engl J Med"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf511\/64102275\/zwaf511.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/7\/1274\/64102275\/zwaf511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/7\/1274\/64102275\/zwaf511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:43:00Z","timestamp":1778866980000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/7\/1274\/8239184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,8,21]]},"published-print":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf511","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,8,21]]}}}